Literature DB >> 14585353

Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Ji Luo1, Brendan D Manning, Lewis C Cantley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14585353     DOI： 10.1016/s1535-6108(03)00248-4

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  467 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

2.  Akt is negatively regulated by the MULAN E3 ligase.

Authors:  Seunghee Bae; Sun-Yong Kim; Jin Hyuk Jung; Yeongmin Yoon; Hwa Jun Cha; Hyunjin Lee; Karam Kim; Jongran Kim; In-Sook An; Jongdoo Kim; Hong-Duck Um; In-Chul Park; Su-Jae Lee; Seon Young Nam; Young-Woo Jin; Jae Ho Lee; Sungkwan An
Journal:  Cell Res       Date:  2012-03-13       Impact factor: 25.617

Review 3.  Isobavachalcone: an overview.

Authors:  Victor Kuete; Louis P Sandjo
Journal:  Chin J Integr Med       Date:  2012-07-07       Impact factor: 1.978

Review 4.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

5.  Repair of Tympanic Membrane Perforations with Customized Bioprinted Ear Grafts Using Chinchilla Models.

Authors:  Che-Ying Kuo; Emmanuel Wilson; Andrew Fuson; Nidhi Gandhi; Reza Monfaredi; Audrey Jenkins; Maria Romero; Marco Santoro; John P Fisher; Kevin Cleary; Brian Reilly
Journal:  Tissue Eng Part A       Date:  2017-09-01       Impact factor: 3.845

Review 6.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

Review 7.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

8.  Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.

Authors:  Yan Liu; Fan Liu; Hao Yu; Xinyang Zhao; Goro Sashida; Anthony Deblasio; Michael Harr; Qing-Bai She; Zhenbang Chen; Hui-Kuan Lin; Silvana Di Giandomenico; Shannon E Elf; Youyang Yang; Yasuhiko Miyata; Gang Huang; Silvia Menendez; Ingo K Mellinghoff; Neal Rosen; Pier Paolo Pandolfi; Cyrus V Hedvat; Stephen D Nimer
Journal:  Sci Signal       Date:  2012-10-23       Impact factor: 8.192

9.  Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.

Authors:  Lizhou Jia; Shiwu Zhang; Yanfen Ye; Xin Li; Imelda Mercado-Uribe; Robert C Bast; Jinsong Liu
Journal:  Cancer Lett       Date:  2012-08-15       Impact factor: 8.679

10.  Fine-tuning AKT kinase activity through direct lysine methylation.

Authors:  Jianping Guo; Wenyi Wei
Journal:  Cell Cycle       Date:  2019-05-03       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.